Evolution of EuroQoL


The EQ-5D and the EuroQol Group

Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol

EQ-5D-Y as a Health-Related Quality of Life Instrument for Children and Adolescents: The Instrument's Characteristics, Development, Current Use, and Challenges of Developing Its Value Set

Effect of Health State Sampling Methods on Model Predictions of EQ-5D-5L Values: Small Designs Can Suffice

Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?

Selecting Bolt-On Dimensions for the EQ-5D: Examining Their Contribution to Health-Related Quality of Life

Future Directions in Valuing Benefits for Estimating QALYs: Is Time Up for the EQ-5D?

 

Back to the Future


“Back to the Future” With Value in Health

Valuing Health: Evolution, Revolution, Resistance, and Reform

Combining Health and Outcomes Beyond Health in Complex Evaluations of Complex Interventions: Suggestions for Economic Evaluation

Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies

Exploring the Internal Structure of the EQ-5D Using Non–Preference-Based Methods

PROMIS® Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains

Future of Patients in Healthcare Evaluation: The Patient-Informed Reference Case

Caring for Carers: Positive and Normative Challenges for Future Research on Carer Spillover Effects in Economic Evaluation

Association Between Patient Experience With Patient-Reported Outcome Measurements and Overall Satisfaction With Care in Neurology

Now Is the Time for Transparency in Value-Based Healthcare Decision Modeling

Multivariable and Structural Uncertainty Analyses for Cost-Effectiveness Estimates: Back to the Future

R You Still Using Excel? The Advantages of Modern Software Tools for Health Technology Assessment

Using Machine Learning Applied to Real-World Healthcare Data for Predictive Analytics: An Applied Example in Bariatric Surgery

Real-World Evidence, Causal Inference, and Machine Learning

Health Technology Assessment Challenges in Oncology: 20 Years of Value in Health

Early Assessment of Proof-of-Problem to Guide Health Innovation

Looking Backward 2143-1943: The Rise and Fall of the RCT

“Time Traveling Is Just Too Dangerous” but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier

Comparing the Noncomparable: The Need for Equivalence Measures That Make Sense in Health-Economic Evaluations

Evolving Use of Real-World Evidence for Devices: Good for Patients, Good for Policy Makers

ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products

 

Curative Therapies


A Beginner's Guide to Understanding Curative Therapies

Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System

Are Global Health Systems Ready for Transformative Therapies?

Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?

Defining and Managing High-Priced Cures: Healthcare Payers’ Opinions

New Cost-Effectiveness Methods to Determine Value-Based Prices for Potential Cures: What Are the Options?
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×